{"analyses":[{"ciLowerLimit":"0.51","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.56","groupDescription":"Analysis of olaparib 200 or 400 mg bd (n=64) versus liposomal doxorubicin (n=33). A hazard ratio \\< 1 favours olaparib.","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.6604","pValueComment":"If the observed p-value for the combined olaparib groups is \\<0.02 (1-sided) then the result will be regarded as statistically significant.","paramType":"Hazard Ratio (HR)","paramValue":"0.88","statisticalComment":"Cox proportional hazards model with factors for treatment, BRCA (1 or 2) and platinum sensitivity (sensitive=1 or resistant/refractory=0).","statisticalMethod":"Regression, Cox"},{"ciLowerLimit":"0.48","ciPctValue":"95","ciUpperLimit":"1.74","groupDescription":"Analysis of olaparib 200 (n=32) versus liposomal doxorubicin (n=33). A hazard ratio \\< 1 favours olaparib.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.7794","pValueComment":"An observed p-value of \\<0.005 (1-sided) will be regarded as statistically significant for a given pairwise comparison.","paramType":"Hazard Ratio (HR)","paramValue":"0.91","statisticalComment":"Cox proportional hazards model with factors for treatment, BRCA (1 or 2) and platinum sensitivity (sensitive=1 or resistant/refractory=0).","statisticalMethod":"Regression, Cox"},{"ciLowerLimit":"0.45","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.62","groupDescription":"Analysis of olaparib 400 (n=32) versus liposomal doxorubicin (n=33). A hazard ratio \\< 1 favours olaparib.","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.6604","pValueComment":"An observed p-value of \\<0.005 (1-sided) will be regarded as statistically significant for a given pairwise comparison.","paramType":"Hazard Ratio (HR)","paramValue":"0.86","statisticalComment":"Cox proportional hazards model with factors for treatment, BRCA (1 or 2) and platinum sensitivity (sensitive=1 or resistant/refractory=0).","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"33"}],"units":"Participants"}],"description":"PFS was defined as the time to progression from the date of randomisation until the date of radiological assessment of progression per RECIST criteria or death (by any cause in the absence of progression)","groups":[{"description":"Olaparib (AZD2281) 200 mg oral capsules twice daily","id":"OG000","title":"Olaparib 200 mg bd"},{"description":"Olaparib (AZD2281) 400 mg oral capsules twice daily","id":"OG001","title":"Olaparib 400 mg bd"},{"description":"Liposomal doxorubicin 50 mg/m2 intravenously every 4 weeks","id":"OG002","title":"Liposomal Doxorubicin"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Tumour assessment was to be assessed at screening, every 8 weeks during the study and at the withdrawal visit, up to 56 weeks. (Data cut-off for primary analysis of PFS: 15 September 2009)","title":"Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Participants"}